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Background: Aberrant DNA methylation at the 5-carbon on cytosine residues (5mC) in CpG dinucleotides is
probably the most extensively characterized epigenetic modification in colon cancer. It has been suggested that
the loss of adenomatous polyposis coli (APC) function initiates tumorigenesis and that additional genetic and
epigenetic events are involved in colon cancer progression. We aimed to study the genome-wide DNA methylation
profiles of intestinal tumorigenesis in Apcmin/+ mice.
Results: Methylated DNA immunoprecipitation (MeDIP) followed by next-generation sequencing was used to
determine the global profile of DNA methylation changes in Apcmin/+ mice. DNA was extracted from adenomatous
polyps from Apcmin/+ mice and from normal intestinal tissue from age-matched Apc+/+ littermates, and the MeDIP-seq
assay was performed. Ingenuity Pathway Analysis (IPA) software was used to analyze the data for gene interactions. A
total of 17,265 differentially methylated regions (DMRs) displayed a≥ 2-fold change (log2) in methylation in Apc
min/+
mice; among these DMRs, 9,078 (52.6 %) and 8,187 (47.4 %) exhibited increased and decreased methylation,
respectively. Genes with altered methylation patterns were mainly mapped to networks and biological functions
associated with cancer and gastrointestinal diseases. Among these networks, several canonical pathways, such as
the epithelial-mesenchymal transition (EMT) and Wnt/β-catenin pathways, were significantly associated with
genome-wide methylation changes in polyps from Apcmin/+ mice. The identification of certain differentially
methylated molecules in the EMT and Wnt/β-catenin pathways, such as APC2 (adenomatosis polyposis coli 2),
SFRP2 (secreted frizzled-related protein 2), and DKK3 (dickkopf-related protein 3), was consistent with previous
publications.
Conclusions: Our findings indicated that Apcmin/+ mice exhibited extensive aberrant DNA methylation that
affected certain signaling pathways, such as the EMT and Wnt/β-catenin pathways. The genome-wide DNA
methylation profile of Apcmin/+ mice is informative for future studies investigating epigenetic gene regulation in
colon tumorigenesis and the prevention of colon cancer.
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It is widely accepted that the accumulation of genetic
and epigenetic alterations contributes to cancer initi-
ation and progression. Genetic alterations refer to muta-
tions in tumor suppressor genes and oncogenes, whereas
epigenetic modifications involve changes in chromatin
structure that result in altered gene expression without
primary changes to the DNA sequence [1]. The informa-
tion conveyed by epigenetic modifications plays a vital
role in regulating DNA-mediated processes, including
transcription, DNA repair, and replication [2]. Specific-
ally, aberrant DNA methylation at the 5-carbon on cyto-
sine residues (5mC) in CpG dinucleotides is perhaps the
most extensively characterized epigenetic modification
in cancer. DNA methylation affects the rate of gene
transcription and therefore regulates various biological
processes, such as proliferation, apoptosis, DNA repair,
cancer initiation, and cancer progression [3]. The gen-
omic DNA methylation pattern is stably maintained in
normal cells; however, aberrant alterations in the epige-
nome have been identified in tumor cells [4]. Evidence
suggests that global hypomethylation and regional hyper-
methylation are characteristics of cancer cells [5]. Global
genome-wide loss of methylation has been associated with
increased genomic instability and proto-oncogene activa-
tion, whereas DNA hypermethylation of CpG islands in
promoter regions silences tumor suppressor genes [6].
Unlike genetic mutations, the transcriptional repression of
genes via epigenetic alterations can be reversed by further
epigenetic modifications because these silenced genes re-
main genetically intact [7]. Thus, it is very important to
profile the global DNA methylation changes that occur in
early tumorigenesis.
Colorectal cancer (CRC) is the second leading cause of
cancer-related death in western countries [8], and more
than 80 % of CRC patients harbor a mutation in the aden-
omatous polyposis coli (APC) gene on chromosome 5q21
[9]. APC is a tumor suppressor gene that down-regulates
the pro-proliferative Wnt-signaling pathway by promoting
the destruction of β-catenin. Deleterious mutations in
APC stabilize β-catenin, increase its translocation into the
nucleus, promote its binding to the transcription factor
TCF4, and activate target genes such as C-MYC and
CCND1 [10, 11]. It has been suggested that the loss of
APC function initiates tumorigenesis and that additional
genetic and epigenetic events are involved in colon cancer
progression [12]. Numerous genes that are silenced by
epigenetic mechanisms have been identified in colon can-
cer, including CDKN2A [13], DKK1 [14], DLEC1 [15, 16],
UNC5C [17], and SFRP [18]. However, the genome-wide
profile of the aberrant methylation and the association of
these methylation patterns with important signaling path-
ways and biological networks implicated in colon tumori-
genesis remain unclear.To address this issue, we examined the global DNA
methylation profile in the well-established Apcmin/+ intes-
tinal tumorigenesis mouse model using methylated DNA
immunoprecipitation (MeDIP) and next-generation se-
quencing (MeDIP-seq). Apcmin/+ mice carry a heterozy-
gous mutation in Apc and develop approximately 30 small
intestinal adenomatous polyps following the somatic loss
of functional Apc [19]. This mouse model of intestinal
tumorigenesis is commonly used because the phenotype
resembles that of patients with familial adenomatous
polyposis (FAP) [20]. We analyzed adenomatous polyps
from Apcmin/+ mice and not only identified genes with a
modified methylation profile but also interpreted the data
in the context of biological function, networks, and ca-




To identify changes in DNA methylation patterns during
the progression of mouse intestinal polyps, whole-
genome DNA methylation analysis was performed using
the described MeDIP-seq method. The global differences
in the DNA methylation profile between adenomatous
polyps from Apcmin/+ mice and intestinal tissue from
control mice are described in Fig. 1. We identified
12,761,009 mapped peaks and 2,868,549 non-mapped
peaks from a total of 15,629,558 peaks in control mice
and 11,470,541 mapped peaks and 2,262,073 non-
mapped peaks from a total of 13,732,614 peaks in Apc-
min/+ mice (Fig. 1a). A total of 17,265 differentially meth-
ylated regions (DMRs) had a ≥ 2-fold change (log2) in
methylation in Apcmin/+ mice compared with control
mice, of which 9,078 DMRs (52.6 %) exhibited increased
methylation, and 8,187 (47.4 %) DMRs exhibited de-
creased methylation (Fig. 1b).
Functional and pathway analysis by IPA
To identify the biological function, networks, and canon-
ical pathways that were affected by the differentially
methylated genes, we performed Ingenuity Pathway
Analysis (IPA) after the MeDIP-seq analysis. In the ana-
lysis of genes with altered methylation (≥2-fold in log2)
in Apcmin/+ mice compared with control mice as deter-
mined by MeDIP-seq, IPA mapped 5,464 unique genes
that were associated with its knowledge base. The top 50
genes with increased and decreased methylation levels
based on log2 fold change are listed in Tables 1 and 2.
The molecules with methylation changes were mainly
categorized into 38 disease and biological functions. The
five highest IPA-rated disease and biological functions
were as follows: cancer, gastrointestinal disease, organis-
mal injury and abnormalities, cellular growth and prolif-
eration, and reproductive system disease (Fig. 2). Among
A B
Fig. 1 Global changes in the DNA methylation profile between Apc mutant adenomatous polyps and control tissue. a, Total number of peaks
generated by MeDIP-seq. b, Number of DMRs with significantly increased or decreased changes in methylation (≥2-fold in log2) in polyps from
Apcmin/+ mice
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terns in polyps from Apcmin/+ mice, 3,299 were associ-
ated with cancer, and 1,668 were associated with
gastrointestinal diseases. To examine the interaction net-
works that were affected by DNA methylation in Apc
mutant polyps, IPA identified 25 networks with up to 35
focus molecules in each network. The five most affected
gene networks as determined by IPA are shown in
Table 3, and the detailed interactions in the most signifi-
cant networks (cancer, cell cycle, and molecular trans-
port) are presented in Fig. 3. In accordance with the
most relevant biological functions as determined by IPA,
genes with different methylation patterns predominantly
mapped to the networks associated with cancer and
gastrointestinal diseases. Taken together, these results
suggested an important role for the altered methylation
of genes associated with the development of cancer and
gut disease in Apcmin/+ mice.
Canonical pathways associated with methylation changes
in Apc mutant polyps were analyzed based on the ratio of
the number of input genes to the total number of reference
genes in the corresponding pathways in the IPA knowledge
bases. Fisher’s exact test was employed to calculate the P
values to determine whether the associations between the
differentially methylated genes and the canonical pathways
were significant or random. Using a cutoff value of P < 0.05,
IPA identified 84 significant signaling pathways that con-
tained genes with increased or decreased methylation. The
15 most significant pathways that correlated with methyla-
tion changes in polyps are presented in Fig. 4. Notably,
regulation of the epithelial-mesenchymal transition (EMT)
pathway was mapped by IPA and ranked as the 4th most
significant canonical pathway associated with altered
methylation. According to the IPA knowledge bases, the
regulation of the EMT pathway includes 196 molecules.
Among these molecules, 62 displayed greater than a 2 fold
change (log2) in methylation in the polyps from Apc
min/+
mice by MeDIP-seq. The abnormal methylation changes inthe EMT pathway included alterations in the methylation
profiles of kinases, peptidases, phosphatases, transcription
regulators, transmembrane receptors, and microRNAs.
Tables 4 and 5 lists the genes involved in the EMT pathway
that exhibited altered methylation (37 genes with increased
methylation in Table 4; 25 genes with decreased methyla-
tion in Table 5). Signaling pathways, such as the Wnt/β-ca-
tenin, TGF-β, NOTCH, and receptor tyrosine kinase
(RTK) pathways, can initiate an EMT program alone or
in combination [21]. Although the genes that were de-
termined to have differential methylation patterns in
polyps by MeDIP-seq were not significantly associated
with the TGF-β, NOTCH, and RTK signaling pathways,
the Wnt/β-catenin pathway was identified as one of the
most significant canonical pathways implicated based
on methylation changes in the polyps (ranked 11th).
Specifically, 53 out of 175 molecules in this pathway
showed methylation changes of greater than 2-fold
(log2) in polyps from Apc
min/+ mice; these molecules
are listed in Tables 6 and 7 (30 genes with increased
methylation in Table 6; 23 genes with decreased methy-
lation in Table 7). Additionally, we found many shared
genes in the EMT and Wnt/β-catenin pathways with al-
tered methylation levels; these genes are shown in bold
in Tables 4, 5, 6 and 7. To understand the role of DNA
methylation in the crosstalk between the EMT and
Wnt/β-catenin pathways in Apcmin/+ mice, IPA was uti-
lized to predict the direct interaction of the differen-
tially methylated genes in these two pathways based on
the publication database (Fig. 5). The pathway analysis
of the MeDIP-seq data suggested that cellular changes
mediated via the EMT and Wnt/β-catenin pathways
may be significantly associated with altered DNA
methylation in polyps from Apcmin/+ mice.
Discussion
Global hypomethylation and hypermethylation of CpG
islands in tumor suppressor genes occurs in human
Table 1 Top 50 annotated genes with increased methylation
Rank Symbol Gene name log2 Fold
Change
Location Type(s)
1 ZNF330 zinc finger protein 330 4.614 Nucleus other
2 ACTR3B ARP3 actin-related protein 3 homolog B (yeast) 4.540 Other other
3 CAV3 caveolin 3 4.292 Plasma
Membrane
enzyme
4 NKX2-3 NK2 homeobox 3 4.199 Nucleus transcription regulator
5 TLN2 talin 2 4.199 Nucleus other
6 CPD carboxypeptidase D 4.100 Extracellular
Space
peptidase
7 CTNNBL1 catenin, beta like 1 4.100 Nucleus other
8 Vmn2r1 vomeronasal 2, receptor 1 4.100 Plasma
Membrane
other
9 Cmtm2a CKLF-like MARVEL transmembrane domain containing 2A 3.993 Cytoplasm transcription regulator
10 HPS6 Hermansky-Pudlak syndrome 6 3.993 Cytoplasm other
11 KANK1 KN motif and ankyrin repeat domains 1 3.993 Nucleus transcription regulator
12 RRP1 ribosomal RNA processing 1 3.993 Nucleus other
13 SNX10 sorting nexin 10 3.993 Cytoplasm transporter
14 UNC93A unc-93 homolog A (C. elegans) 3.993 Plasma
Membrane
other
15 Zfp932 zinc finger protein 932 3.993 Nucleus other
16 ANKRD13D ankyrin repeat domain 13 family, member D 3.877 Plasma
Membrane
other
17 DACT1 dishevelled-binding antagonist of beta-catenin 1 3.877 Cytoplasm other
18 DMRT2 doublesex and mab-3 related transcription factor 2 3.877 Nucleus other
19 DSC3 desmocollin 3 3.877 Plasma
Membrane
other
20 LDOC1 leucine zipper, down-regulated in cancer 1 3.877 Nucleus other
21 LRRC8B leucine rich repeat containing 8 family, member B 3.877 Other other
22 SEPP1 selenoprotein P, plasma, 1 3.877 Extracellular
Space
other
23 SMAD3 SMAD family member 3 3.877 Nucleus transcription regulator
24 Smok2a sperm motility kinase 2B 3.877 Other other
25 TCEAL3 transcription elongation factor A (SII)-like 3 3.877 Other other
26 TNS1 tensin 1 3.877 Plasma
Membrane
other
27 TRHR thyrotropin-releasing hormone receptor 3.877 Plasma
Membrane
G-protein coupled receptor
28 WWC1 WW and C2 domain containing 1 3.877 Cytoplasm transcription regulator
29 PER2 period circadian clock 2 3.853 Nucleus other




32 KCNF1 potassium voltage-gated channel, subfamily F, member 1 3.752 Plasma
Membrane
ion channel
33 MPP1 membrane protein, palmitoylated 1, 55 kDa 3.752 Plasma
Membrane
kinase
34 OPA1 optic atrophy 1 (autosomal dominant) 3.752 Cytoplasm enzyme
35 PTP4A1 protein tyrosine phosphatase type IVA, member 1 3.752 Cytoplasm phosphatase
36 SGCZ sarcoglycan, zeta 3.752 other
Guo et al. Cell & Bioscience  (2015) 5:24 Page 4 of 17
Table 1 Top 50 annotated genes with increased methylation (Continued)
Plasma
Membrane
37 ADCY7 adenylate cyclase 7 3.614 Plasma
Membrane
enzyme
38 ALCAM activated leukocyte cell adhesion molecule 3.614 Plasma
Membrane
other
39 AR androgen receptor 3.614 Nucleus ligand-dependent
nuclear receptor
40 C4orf33 chromosome 4 open reading frame 33 3.614 Other other
41 CCNH cyclin H 3.614 Nucleus transcription regulator
42 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 3.614 Nucleus kinase
43 CDV3 CDV3 homolog (mouse) 3.614 Cytoplasm other
44 COMT catechol-O-methyltransferase 3.614 Cytoplasm enzyme
45 CRYGC crystallin, gamma C 3.614 Cytoplasm other
46 FAM13A family with sequence similarity 13, member A 3.614 Cytoplasm other
47 IGF1R insulin-like growth factor 1 receptor 3.614 Plasma
Membrane
transmembrane receptor
48 IYD iodotyrosine deiodinase 3.614 Plasma
Membrane
enzyme
49 JAG1 jagged 1 3.614 Extracellular
Space
growth factor
50 KCNMA1 potassium large conductance calcium-activated channel,
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tissues [12]. However, the global genomic distribution of
aberrant methylation and the association of these methy-
lation signatures with pivotal signaling pathways and
biological networks in colon cancer remain unclear,
mainly due to the limitations of the existing techniques
for analyzing DNA methylation at specific sequences
[22]. Recently, the development of the MeDIP-based ap-
proach has enabled the rapid and comprehensive identi-
fication of multiple CpG sites. MeDIP in conjunction
with high-throughput sequence (MeDIP-seq) provides a
genome-wide mapping technique that has been success-
fully used to profile the global DNA methylation pat-
terns of many cancer models [23–26]. Notably, Grimm
et al. used MeDIP-seq to identify a large number of
DMRs with distinct methylation patterns in Apc mutant
adenomas, which are partially conserved between intes-
tinal adenomas in Apcmin/+ mice and human colon can-
cer [27]. In the present study, we used pathway analysis
after MeDIP-seq to screen the global genomic methyla-
tion profile to identify genomic loci with aberrant
methylation patterns in adenomatous polyps from Apc-
min/+ mice and to determine the biological function, net-
works, and canonical pathways that were affected by the
DNA methylation in Apc mutant adenomas.
The top-ranked genes with increased and decreased
methylation may provide information to facilitate thediscovery of key genes, therapeutic targets, and bio-
markers for the development, diagnosis, prognosis, and
prevention of colon cancer. For example, CTNNBL1 [ca-
tenin (cadherin-associated protein) b-like 1] exhibited in-
creased methylation in adenomatous polyp tissue (log2
fold change = 4.1, Table 1), as evidenced by MeDIP-seq.
The CTNNBL1 gene is associated with obesity, a known
risk factor for the development of CRC [28]. Recently,
CTNNBL1 was reported to be a putative regulator of the
canonical Wnt signaling pathway, and mutations in and
dysregulation of this pathway are involved in CRC [29].
However, the potential epigenetic regulation of CTNNBL1
in colon cancer remains to be elucidated. To the best of
our knowledge, this is the first report to suggest that
CTNNBL1 might by aberrantly methylated in Apc mutant
mice. Further experiments are necessary to investigate the
epigenetic regulation of CTNNBL1 in colon cancer cells
and patient specimens. CDKN1A (cyclin-dependent kin-
ase inhibitor 1A, p21) showed increased methylation (log2
fold change = 3.6, Table 1) in adenomatous polyp tissue
compared with control tissue. CDKN1A is a cyclin-
dependent kinase inhibitor that plays a key role in regulat-
ing the cell cycle, especially the G1/S checkpoint, and its
expression is lost in most cases of colon cancer. By analyz-
ing 737 CRC samples, Ogino et al. concluded that the
down-regulation of p21 inversely correlates with microsat-
ellite instability and the CpG island methylator phenotype
Table 2 Top 50 annotated genes with decreased methylation
Rank Symbol Gene name log2 Fold
Change
Location Type(s)
1 IRX1 iroquois homeobox 1 −5.897 Nucleus transcription regulator
2 OSBP2 oxysterol binding protein 2 −5.408 Cytoplasm other
3 CAPN5 calpain 5 −5.231 Cytoplasm peptidase
4 INTS9 integrator complex subunit 9 −4.837 Nucleus other
5 TRIML1 tripartite motif family-like 1 −4.837 Other other
6 CSMD1 CUB and Sushi multiple domains 1 −4.614 Plasma Membrane other
7 NCOR2 nuclear receptor corepressor 2 −4.272 Nucleus transcription regulator
8 C6orf89 chromosome 6 open reading frame 89 −4.167 Other other
9 TMEM242 transmembrane protein 242 −4.167 Other other
10 DCLRE1A DNA cross-link repair 1A −4.100 Nucleus other




13 PTPN11 protein tyrosine phosphatase, non-receptor type 11 −3.877 Cytoplasm phosphatase
14 AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 −3.795 Cytoplasm enzyme
15 IER5 immediate early response 5 −3.795 Other other
16 PPM1D protein phosphatase, Mg2+/Mn2+ dependent, 1D −3.708 Cytoplasm phosphatase
17 RBBP6 retinoblastoma binding protein 6 −3.708 Nucleus enzyme
18 BLOC1S2 biogenesis of lysosomal organelles complex-1, subunit 2 −3.614 Cytoplasm other
19 CPEB2 cytoplasmic polyadenylation element binding protein 2 −3.614 Cytoplasm other
20 ECI2 enoyl-CoA delta isomerase 2 −3.614 Cytoplasm enzyme
21 MMGT1 membrane magnesium transporter 1 −3.614 Cytoplasm transporter
22 NALCN sodium leak channel, non-selective −3.614 Plasma Membrane ion channel
23 RETNLB resistin like beta −3.614 Extracellular Space other
24 AMD1 adenosylmethionine decarboxylase 1 −3.515 Cytoplasm enzyme
25 C1orf198 chromosome 1 open reading frame 198 −3.515 Other other
26 DGKI diacylglycerol kinase, iota −3.515 Cytoplasm kinase
27 DYNLT3 dynein, light chain, Tctex-type 3 −3.515 Cytoplasm other
28 EPHA6 EPH receptor A6 −3.515 Plasma Membrane kinase
29 GABRA6 gamma-aminobutyric acid (GABA) A receptor, alpha 6 −3.515 Plasma Membrane ion channel
30 Gk2 glycerol kinase 2 −3.515 Cytoplasm other
31 GLT1D1 glycosyltransferase 1 domain containing 1 −3.515 Extracellular Space enzyme
32 HMGN2 high mobility group nucleosomal binding domain 2 −3.515 Nucleus other
33 KLHL17 kelch-like family member 17 −3.515 Cytoplasm other
34 Olfr266 olfactory receptor 266 −3.515 Plasma Membrane G-protein coupled receptor
35 Ott ovary testis transcribed −3.515 Other other
36 P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7 −3.515 Plasma Membrane ion channel
37 PTER phosphotriesterase related −3.515 Other enzyme
38 Rnf213 ring finger protein 213 −3.515 Cytoplasm enzyme
39 SERPINC1 serpin peptidase inhibitor, clade C (antithrombin), member 1 −3.515 Extracellular Space enzyme
40 TPD52L1 tumor protein D52-like 1 −3.515 Cytoplasm other
41 ZMAT4 zinc finger, matrin-type 4 −3.515 Nucleus other
42 RBM20 RNA binding motif protein 20 −3.462 Nucleus other
43 BEGAIN brain-enriched guanylate kinase-associated −3.408 Nucleus other
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Table 2 Top 50 annotated genes with decreased methylation (Continued)
44 CHSY3 chondroitin sulfate synthase 3 −3.408 Cytoplasm enzyme
45 CKAP4 cytoskeleton-associated protein 4 −3.408 Cytoplasm other
46 DPF3 D4, zinc and double PHD fingers, family 3 −3.408 Other other
47 Ear2 eosinophil-associated, ribonuclease A family, member 2 −3.408 Cytoplasm enzyme
48 FAM135B family with sequence similarity 135, member B −3.408 Other enzyme
49 POT1 protection of telomeres 1 −3.408 Nucleus other
50 POU6F1 POU class 6 homeobox 1 −3.408 Nucleus transcription regulator
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dence by demonstrating potentially increased p21 methy-
lation in Apcmin/+ polyps.
It is commonly believed that promoter hypermethyla-
tion is associated with silencing of tumor suppressor
genes in carcinogenesis [31]. One study observed a sig-
nificant increase in DNA methylation in primary colon
adenocarcinoma samples relative to normal colon tissue
by analyzing the DNA methylation data from Cancer
Genome Atlas (TCGA) and found an inverse correlation
between DNA methylation and gene expression: genes
with cancer-specific DNA methylation showed decreased
transcription activity in colon adenocarcinoma [32].
However, Grimm et al. reported that the correlation of
gene expression and DNA methylation applies only to a
small set of genes by analyzing the results from MeDIP-
seq and RNA-seq in normal intestine tissues and Apc
mutant adenomas. In addition, they analyzed the mRNA
expression of 31 selected tumor suppressors, only 2 wereFig. 2 The 5 most significant biological functions and diseases
related to changes in the methylation patterns. The number of
molecules in the dataset associated with a known function was
determined by IPA functional analysisfound both promoter hypermethylated and transcrip-
tionally silenced. Surprisingly, the majority of tumor
suppressors examined in their study did not exhibit a
decreased transcriptional activity in adenoma compared
to normal intestine samples [27]. These results suggested
that silencing of tumor suppressor genes by aberrant
methylation may not be common events during early
polyposis of Apc mutant mice. Nevertheless, it is pos-
sible that epigenetic changes mediated gene silencing
arises during progression of adenoma to carcinoma [33].
Furthermore, it was reported that instead of directly
intervene active promoters, DNA methylation affects
genes that are already silent by other mechanisms such
as histone modifications [34]. Thus, further studies are
needed to elucidate the dynamic changes of DNA
methylation, histone modifications, and gene transcrip-
tion in different stages, such as initiation, progression,
and metastasis during colon carcinogenesis.
This study aimed to discover functions and pathways
associated with epigenomic alterations in colon cancer
in addition to the individual affected molecules. We uti-
lized IPA to interpret the MeDIP-seq data in the context
of molecular interactions, networks, and canonical path-
ways. IPA revealed that the genes with altered methyla-
tion patterns in adenomatous tissues predominantly
occupied the cancer and cell cycle networks (Table 3)
and the cancer and gastrointestinal disease functional
categories (Fig. 2). This information suggested that dy-
namic epigenetic modifications might occur in genes as-
sociated with cancer, cell cycle regulation, and gut
disease development in Apcmin/+ mice.
Biological changes that lead to the switch from an epi-
thelial to a mesenchymal cell phenotype, defined as
EMT, play an important role in embryonic development
and carcinogenesis [35]. In the context of tumorigenesis-
associated EMT, neoplastic cells lose epithelial charac-
teristics, such as cell-cell adhesion, cell polarity, and lack
of motility, and acquire mesenchymal features, such as
migratory ability, invasiveness, plasticity, and resistance
to apoptosis [21]. The morphological alterations that
occur during EMT enable neoplastic cells to escape from
Table 3 Ingenuity Pathway Analysis of gene networks




↑EID2, ↓ELAC2, ↑EPB41L2, ↑EPB41L3, ↑FRMD6, ↑KIAA0195, ↑MAGEB1, ↑MBNL1,
↑MBNL2, ↑N4BP2L2, ↓NKD2, ↑NSA2, ↑RASSF4, ↓RASSF8, ↑RNF34, ↓SERPINI2,
↑SLC30A5, ↓SLC30A6, ↑SP110, ↑SP140, ↓SPAG5, ↑SYF2, ↓TROAP, ↑TXNDC11,
↑VGLL4, ↑WNT16, ↑WWC1
30 35 Cancer, Cell Cycle, Molecular Transport
2 ↑ACACA, ↓ATRNL1, ↓BHMT, ↑CYP2A13, ↓Cyp2c70, ↑CYP3A43, ↓DCLRE1A,
↑E330013P04Rik, ↓FASN, ↑GPC6, ↑GSTP1, ↓HNMT, ↓IVNS1ABP, ↓Keg1, ↓Lcn4,
↑LRTM1, ↓MC4R, ↓Mill1, ↑MRGPRX3, ↑MT1E, ↑MTF1, ↑NR1H4, ↑RORA,
↑SLC13A1, ↑SLC16A7, ↓SLC29A4, ↓SLC30A1, ↓SLC38A4, ↑SULT1C3, ↓TMC6,
↓UCP1, ↑UPP2, ↓Xlr3c (includes others), ↑ZNF275, ↓ZNF292
30 35 Renal Damage, Renal Tubule Injury,
Molecular Transport
3 ↑ABTB2, ↑ALKBH8, ↑ALPK1, ↓BCKDHB, ↑BTBD7, ↑C11orf70, ↑C20orf194,
↑CAMKV, ↓CCDC39, ↑CUL2, ↓CUL3, ↑DCLK2, ↑EGFLAM, ↑FAM98A, ↓FARS2,
↑FBXO10, ↑FBXO34, ↑G2E3, ↓G3BP2, ↑HSP90AA1, ↓KCNG1, ↓KCNS3, ↓KCTD8,
↑KLHL10, ↓KLHL14, ↑KLHL29, ↑KLHL32, ↑KLHL36, ↑KRR1, ↑QDPR, ↑RCBTB1,
↓SEPHS1, ↓UST, ↓YWHAE, ↑ZBED4
30 35 Hereditary Disorder, Respiratory Disease,
Metabolic Disease
4 ↓ABCA6, ↓ABLIM3, ↓ABRA, ↑AIF1L, ↓AMBRA1, ↓ARAP2, ↓ARL6, ↓ATL2, ↓CAPN5,
↑CAPN6, ↓CASP12,CD80/CD86, ↑CLEC2D, ↑CLEC6A, ↑CRTAM, ↑GBP5,
↑Gbp8,Gbp6 (includes others), ↑GFM1, ↑GIMAP1-GIMAP5, ↑Gvin1 (includes
others), ↑HERC6, ↑IFNG, ↓KIAA0226, ↓KIF16B,↑KLRB1, ↓KMO, ↓KY, ↑LAMP3,
↑LIX1, ↓Neurl3, ↑PCDH17, ↑Phb, ↑PILRB, ↓PMP2
28 34 Endocrine System Disorders, Gastrointestinal
Disease, Immunological Disease
5 ↑AFF2, ↑AP4S1, ↑ASAP2, ↓C21orf91, ↑C2orf88, ↑DLGAP1, ↑Eif2s3x, ↓FAM110A,
↑GNS, ↑GRB2, ↑HDGFRP3, ↓KCNH7, ↓KIRREL, ↑KRT83, ↑LRFN4, ↑MEPE, ↑NCK1,
↑NCKAP5, ↓PANX2, ↑PHACTR2, ↑RALGAPA2, ↓RALGPS1, ↑SEPN1, ↑SH2D4A,
↑SHANK2, ↓SHROOM2, ↓SLCO2A1, ↑SNX8, ↑SNX12, ↑SNX18, ↓SPRY, ↑TJAP1,
↑TTYH2, ↑WDR44, ↑ZNF32
28 34 Cellular Assembly and Organization, Tissue
Development, Cellular Function and
Maintenance
↑, increased methylation; ↓, decreased methylation
Guo et al. Cell & Bioscience  (2015) 5:24 Page 8 of 17the basement membrane, migrate to neighboring lymph
nodes, and eventually enter the circulation to establish
secondary colonies at distant sites [36]. Thus, EMT pro-
gram activation is considered a critical step in tumor
growth, angiogenesis, and metastasis [37]. Chen et al. re-
ported elevated expression of the mesenchymal marker
vimentin in intestinal adenomas from Apcmin/+ mice and
suggested that molecular alterations in the initial steps
of EMT are involved in early tumorigenesis in Apcmin/+
mice; the early stages of intestinal tumorigenesis lack
signs of invasion and metastasis [38]. These interesting
observations highlighted the necessity to study the EMT
process during early tumorigenesis. Although the mo-
lecular and biochemical mechanisms involved in the ini-
tiation and regulation of EMT in carcinogenesis are not
yet fully understood, they appear to be associated with
growth factor receptors (for example, RTKs), signaling
pathways (for example, the Wnt/β-catenin, NOTCH,
and TGF-β pathways), and stimuli (for example, oxida-
tive stress) [39]. The involvement of epigenetic events in
regulating the EMT proteome during carcinogenesis was
recently demonstrated [40]. Using ChIP-seq (chromatin
immunoprecipitation followed by sequencing) assays,
Cieslik et al. showed that EMT is driven by the
chromatin-mediated activation of transcription factors
[41]. The current study identified many genes withincreased or decreased methylation in the EMT pathway
(Fig. 3, Tables 4 and 5), suggesting that aberrant DNA
methylation may be associated with the activation of
EMT during tissue remodeling in early tumorigenesis in
Apcmin/+ mice. The present study also provided useful
information regarding important molecules in the EMT
pathway that undergo alterations in their methylation
pattern during polyposis in Apcmin/+ mice. For example,
SMAD3 (mothers against decapentaplegic homolog 3), a
molecule that plays an essential role in TGF-β pathway-
mediated EMT, was one of the genes that exhibited in-
creased methylation (log2 fold change = 3.9, Table 4) in
adenomas in Apcmin/+ mice. Interestingly, SMAD3 defi-
ciency promotes tumor formation in the distal colon of
Apcmin/+ mice [42]. EGFR (epidermal growth factor re-
ceptor), another important molecule that exhibited in-
creased methylation, has been implicated in EMT in
adenomas (log2 fold change = 2.9, Table 4). EGFR can in-
duce EMT in cancer cells by up-regulating Twist [43],
and promoter methylation of EGFR has been detected in
metastatic tumors from patients with CRC [44]. The re-
sults of the current study indicated that aberrant methy-
lation of EGFR may occur during early tumorigenesis in
Apcmin/+ mice. Important transcription factors in the
EMT pathway, including ZEB 1 and TWIST 2, also exhib-
ited increased methylation in adenomas from Apcmin/+
Fig. 3 The most significant networks determined by IPA: cancer, cell cycle, and molecular transport. The IPA network analysis was conducted
using the genes that were differentially methylated and their close relationships. IPA used triangle connectivity based on 30 focus genes and
built the network according to the number of interactions between a single gene and others in the existing network. Red, increased methylation;
green, decreased methylation
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promoting EMT in breast cancer progression was recently
reported [45], there is limited knowledge of the role of
TWIST 2 in colon cancer; however, one study proposed
that TWIST 2 is a potential prognostic biomarker for
colon cancer [46]. Notably, aberrant methylation of
TWIST 2 has been demonstrated in chronic lymphocytic
leukemia [47] and acute lymphoblastic leukemia [48]. The
present study is the first to suggest that methylation of theTWIST 2 gene may be involved in tumorigenesis in Apc-
min/+ mice. Further studies are necessary to elucidate the
role of DNA methylation in EMT pathway regulation in
early tumorigenesis in Apcmin/+ mice.
Apcmin/+ mice are thought to have a hyperactive
Wnt/β-catenin pathway [10], but the epigenetic modifi-
cations of the Wnt/β-catenin pathway are still not fully
understood. IPA identified the Wnt/β-catenin pathway
as one of the most significant canonical pathways that
Fig. 4 The 15 most significant canonical pathways related to changes in the methylation patterns. The left y-axis (bar graph) presents the data as
the log (p-value) of each pathway using Fisher’s exact test. The right y-axis (line graph) corresponds to the ratio data for each pathway. The ratios
were calculated as the number of input molecules mapped to a specific pathway divided by the total number of molecules in the given pathway
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tion, suggesting an important role for epigenetic alter-
ations in the Wnt/β-catenin pathway in tumorigenesis.
Some of the molecules with increased or decreased
methylation patterns that were mapped to this pathway
in the present study are consistent with the findings of
previous publications. For example, Dhir et al. analyzed
tissue samples from inflammatory bowel disease (IBD)
and colon cancer patients and demonstrated that aber-
rant methylation of Wnt/β-catenin signaling genes is an
early event in IBD-associated colon cancer. Aberrant
methylation of APC2 (adenomatousis polyposis coli 2),
SFRP1 (secreted frizzled-related protein 1), and SFRP2
(secreted frizzled-related protein 2) is associated with
the progression from colitis to neoplasia [49]. In the
current study, we observed increased methylation of
APC2 and decreased methylation of SFRP2 in aden-
omas in Apcmin/+ mice (Tables 6 and 7). Wang et al.
demonstrated that black raspberries can prevent colonic
ulceration in a DSS-induced model and in interleukin-10
knockout mice by epigenetically modifying genes with
hypermethylated promoters in the Wnt/β-catenin path-
way, such as DKK3 (dickkopf-related protein 3), APC,
SFRP1, and SOX17 [SRY (sex determining region Y)-box
17] [50, 51]. In the present study, DKK3 consistently dis-
played increased methylation (log2 fold change = 2.9,
Table 6) in adenomas from Apcmin/+ mice compared with
normal tissue. Furthermore, we provided additionalinformation regarding the genes with altered methylation
in the Wnt/β-catenin pathway in polyps from Apcmin/+
mice, potentially facilitating future research on the in-
volvement of aberrantly methylated Wnt/β-catenin path-
way components in colon cancer development and on
potential targets for epigenetic modification for the pre-
vention of colon cancer. Intestinal adenoma in mouse
originated from intestinal stem cells (ISC), a small fraction
of cells in proliferative crypts [52]. Interestingly, Grimm
and co-workers demonstrated that the adenoma-specific
methylation signatures are not acquired from ISC by
showing that the methylation patterns were similar in ISC,
proliferative crypt cells, and differentiated villus cells, but
are distinct in adenoma tissue [27]. Since ISC are respon-
sive to Wnt signaling and we identified Wnt/β-catenin
pathway as one of the most significant pathways associ-
ated with DNA methylation in polyps from Apcmin/+ mice,
it would be important to understand the mechanisms
underlying the acquisition of aberrant DNA methylation
patterns in Wnt/β-catenin pathway in adenoma and how
the hypermethylated genes involved in Wnt/β-catenin
pathway influence the neoplastic transformation from ISC
to adenoma. Furthermore, the Wnt/β-catenin pathway is
intimately associated with EMT pathway [53]. The present
study provided valuable information regarding the poten-
tial crosstalk between the EMT and Wnt/β-catenin path-
ways, which are both affected by DNA methylation in
Apcmin/+ mice (Fig. 5). Further studies are needed to
Table 4 Genes with increased methylation that mapped to the regulation of the EMT pathway by IPA
Symbol Gene name log2 Fold
Change
Location Type(s)
SMAD3 SMAD family member 3 3.877 Nucleus transcription regulator
JAG1 jagged 1 3.614 Extracellular Space growth factor
WNT5A wingless-type MMTV integration site family, member 5A 3.292 Extracellular Space cytokine
FGF13 fibroblast growth factor 13 3.100 Extracellular Space growth factor
WNT10A wingless-type MMTV integration site family, member 10A 3.100 Extracellular Space other
EGFR epidermal growth factor receptor 2.877 Plasma Membrane kinase
FGF7 fibroblast growth factor 7 2.877 Extracellular Space growth factor
FGF14 fibroblast growth factor 14 2.877 Extracellular Space growth factor
ID2 inhibitor of DNA binding 2, dominant negative
helix-loop-helix protein
2.877 Nucleus transcription regulator
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit
type 2 alpha
2.877 Cytoplasm kinase
FZD1 frizzled class receptor 1 2.752 Plasma Membrane G-protein coupled receptor
CDH12 cadherin 12, type 2 (N-cadherin 2) 2.614 Plasma Membrane other
FGF8 fibroblast growth factor 8 (androgen-induced) 2.614 Extracellular Space growth factor
FZD8 frizzled class receptor 8 2.614 Plasma Membrane G-protein coupled receptor
JAK2 Janus kinase 2 2.614 Cytoplasm kinase
PIK3C2G phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit
type 2 gamma
2.614 Cytoplasm kinase
ZEB1 zinc finger E-box binding homeobox 1 2.614 Nucleus transcription regulator
GSC goosecoid homeobox 2.462 Nucleus transcription regulator
ADAM17 ADAM metallopeptidase domain 17 2.292 Plasma Membrane peptidase
FGF9 fibroblast growth factor 9 2.292 Extracellular Space growth factor
FGF11 fibroblast growth factor 11 2.292 Extracellular Space growth factor
FGFR2 fibroblast growth factor receptor 2 2.292 Plasma Membrane kinase
FRS2 fibroblast growth factor receptor substrate 2 2.292 Plasma Membrane other
GRB2 growth factor receptor-bound protein 2 2.292 Cytoplasm other
LOX lysyl oxidase 2.292 Extracellular Space enzyme
NCSTN nicastrin 2.292 Plasma Membrane peptidase
PARD6B par-6 family cell polarity regulator beta 2.292 Plasma Membrane other
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit gamma
2.292 Cytoplasm kinase
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 2.292 Cytoplasm kinase
SOS2 son of sevenless homolog 2 (Drosophila) 2.292 Cytoplasm other
TGFB2 transforming growth factor, beta 2 2.292 Extracellular Space growth factor
WNT2 wingless-type MMTV integration site family member 2 2.292 Extracellular Space cytokine
MET MET proto-oncogene, receptor tyrosine kinase 2.180 Plasma Membrane kinase
AKT3 v-akt murine thymoma viral oncogene homolog 3 2.100 Cytoplasm kinase
TWIST2 twist family bHLH transcription factor 2 2.100 Nucleus transcription regulator
WNT2B wingless-type MMTV integration site family, member 2B 2.100 Extracellular Space other
WNT16 wingless-type MMTV integration site family, member 16 2.029 Extracellular Space other
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multiple signaling pathways in the progression of colon
cancer.In addition to DNA methylation, histone modification
and non-coding RNA are major epigenetic mechanisms
that regulate gene transcription in carcinogenesis [54]. It
Table 5 Genes with decreased methylation that mapped to the regulation of the EMT pathway by IPA
Symbol Gene name log2 Fold Change Location Type(s)
PTPN11 protein tyrosine phosphatase, non-receptor type 11 −3.877 Cytoplasm phosphatase
PDGFD platelet derived growth factor D −3.167 Extracellular Space growth factor
RRAS2 related RAS viral (r-ras) oncogene homolog 2 −3.090 Plasma Membrane enzyme
FGF10 fibroblast growth factor 10 −2.877 Extracellular Space growth factor
FGF12 fibroblast growth factor 12 −2.877 Extracellular Space other
CDH2 cadherin 2, type 1, N-cadherin (neuronal) −2.708 Plasma Membrane other
ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1 −2.708 Nucleus transcription regulator
mir-155 microRNA 155 −2.708 Cytoplasm microRNA
PIK3C3 phosphatidylinositol 3-kinase, catalytic subunit type 3 −2.708 Cytoplasm growth factor
PSEN2 presenilin 2 −2.708 Cytoplasm peptidase
TGFB3 transforming growth factor, beta 3 −2.708 Extracellular Space growth factor
SOS1 son of sevenless homolog 1 (Drosophila) −2.515 Cytoplasm other
WNT11 wingless-type MMTV integration site family, member 11 −2.515 Extracellular Space other
SMAD4 SMAD family member 4 −2.292 Nucleus transcription regulator
WNT7A wingless-type MMTV integration site family, member 7A −2.292 Extracellular Space cytokine
SMAD2 SMAD family member 2 −2.167 Nucleus transcription regulator
TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box) −2.167 Nucleus transcription regulator
CLDN3 claudin 3 −2.029 Plasma Membrane transmembrane receptor
GAB1 GRB2-associated binding protein 1 −2.029 Cytoplasm other
HMGA2 – −2.029 Other other
RAF1 Raf-1 proto-oncogene, serine/threonine kinase −2.029 Cytoplasm kinase
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) −2.029 Nucleus transcription regulator
TWIST1 twist family bHLH transcription factor 1 −2.029 Nucleus transcription regulator
WNT7B wingless-type MMTV integration site family, member 7B −2.029 Extracellular Space other
WNT8B wingless-type MMTV integration site family, member 8B −2.029 Extracellular Space other
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are linked to one another in the modulation of the epige-
nome landscape [55, 56]. For example, these epigenetic
modifications may work in combination in carcinogenesis
[57]. It was found that DNA hypermethylation in Apc
mutant adenomas preferentially target the polycomb
repressive complex 1/2 (PRC 1/2) target genes, suggest-
ing an interplay of DNA methylation and histone modi-
fication in Apcmin/+ mice [27]. On the other hand,
different epigenetic mechanisms may cross-regulate
each other in the regulation of cellular activity. For in-
stance, the expression of certain microRNAs is potentially
controlled by DNA methylation or histone modification.
However, some microRNAs can target epigenetic-
modifying enzymes, such as DNMTs (DNA methyltrans-
ferases) and EZH2 (enhancer of zeste homolog 2) [58].
Furthermore, Tahara, et al. found that 74 chromatin regu-
latory genes are mutated more frequently in CpG island
methylator phenotype - high CRC in the TCGA dataset
[59]. Changes in the methylation patterns of several genes
encoding microRNAs, histone modification enzymes, andproteins that function in chromatin remodeling were
identified using MeDIP-seq. For example, we discovered
decreased methylation of microRNA-155 (log2 fold
change = −2.7, Table 5), which mapped to the EMT path-
way; microRNA-155 expression promotes the migration
and invasion of several CRC cell lines [60]. Moreover,
HDAC1 (histone deacetylase 1) was mapped to the
Wnt/β-catenin pathway with a 2.9-fold (log2) increase
in methylation in Apc mutant polyps (Table 6). In
addition, we observed an increased methylation in the
gene coding for chromodomain-helicase-DNA-binding
protein 1 (CHD1) in Apc mutant polyps (data not
shown). CHD1 protein is known to be involved in
transcription-related chromatin remodeling [61]. Taken
together, our data indicated that epigenetic alterations
may be complex and may occur at multiple levels dur-
ing tumorigenesis in Apcmin/+ mice.
Conclusions
In conclusion, polyps from Apcmin/+ mice exhibited exten-
sive, aberrant DNA methylation. The methylation changes
Table 6 Genes with increased methylation that mapped to the Wnt/β-catenin pathway by IPA
Symbol Gene name log2 Fold
Change
Location Type(s)
SOX11 SRY (sex determining region Y)-box 11 3.614 Nucleus transcription regulator
TLE1 transducin-like enhancer of split 1 (E(sp1) homolog,
Drosophila)
3.462 Nucleus transcription regulator
SOX2 SRY (sex determining region Y)-box 2 3.292 Nucleus transcription regulator
WNT5A wingless-type MMTV integration site family, member 5A 3.292 Extracellular Space cytokine
WNT10A wingless-type MMTV integration site family, member 10A 3.100 Extracellular Space other
CDH5 cadherin 5, type 2 (vascular endothelium) 2.877 Plasma Membrane other
DKK3 dickkopf WNT signaling pathway inhibitor 3 2.877 Extracellular Space cytokine
HDAC1 histone deacetylase 1 2.877 Nucleus transcription regulator
PPP2R3A protein phosphatase 2, regulatory subunit B”, alpha 2.877 Nucleus phosphatase
RUVBL2 RuvB-like AAA ATPase 2 2.877 Nucleus transcription regulator
UBD ubiquitin D 2.877 Nucleus other
FZD1 frizzled class receptor 1 2.752 Plasma Membrane G-protein coupled receptor
CDH12 cadherin 12, type 2 (N-cadherin 2) 2.614 Plasma Membrane other
FZD8 frizzled class receptor 8 2.614 Plasma Membrane G-protein coupled receptor
MYC v-myc avian myelocytomatosis viral oncogene homolog 2.614 Nucleus transcription regulator
SOX4 SRY (sex determining region Y)-box 4 2.614 Nucleus transcription regulator
SOX6 SRY (sex determining region Y)-box 6 2.614 Nucleus transcription regulator
APC2 adenomatosis polyposis coli 2 2.292 Cytoplasm enzyme
APPL2 adaptor protein, phosphotyrosine interaction, PH domain
and leucine zipper containing 2
2.292 Cytoplasm other
CSNK2A1 casein kinase 2, alpha 1 polypeptide 2.292 Cytoplasm kinase
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) 2.292 Extracellular Space peptidase
NR5A2 nuclear receptor subfamily 5, group A, member 2 2.292 Nucleus ligand-dependent nuclear receptor
PIN1 peptidylprolyl cis/trans isomerase, NIMA-interacting 1 2.292 Nucleus enzyme
TGFB2 transforming growth factor, beta 2 2.292 Extracellular Space growth factor
WNT2 wingless-type MMTV integration site family member 2 2.292 Extracellular Space cytokine
AKT3 v-akt murine thymoma viral oncogene homolog 3 2.100 Cytoplasm kinase
FRAT1 frequently rearranged in advanced T-cell lymphomas 2.100 Cytoplasm other
WNT2B wingless-type MMTV integration site family, member 2B 2.100 Extracellular Space other
WNT16 wingless-type MMTV integration site family, member 16 2.029 Extracellular Space other
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mainly attributed to functions and networks in cancer, the
cell cycle, and gastrointestinal diseases. These differentially
methylated genes were situated in several canonical path-
ways that are important in colon cancer, such as the EMT
and Wnt/β-catenin signaling pathways.
Materials and methods
Mouse strains
C57BL/6 J male mice that are heterozygous for the Apc
allele (Apcmin/+) and their wild type littermates (Apc+/+)
were originally obtained from Jackson Laboratories (Bar
Harbor, ME, USA). The animals were housed in the Ani-
mal Care Facility at Rutgers University with a 12 h-light/12 h-dark cycle and were provided ad libitum access to
food and water. The Apcmin/+ and control mice were
sacrificed by CO2 inhalation at 20 weeks of age. Polyp and
intestine samples were collected as previously described
[62]. Briefly, after sacrificing the mice, the gastrointestinal
tract was removed, opened longitudinally, and rinsed thor-
oughly with saline. Intestinal adenomatous polyps were
excised from the intestines carefully. The normal intestine
tissue and polyps were snap frozen and stored at −80 °C
for future use.
DNA extraction
Genomic DNA was isolated from adenomatous polyps
from three Apcmin/+ mice and from normal intestinal
Table 7 Genes with decreased methylation that mapped to the Wnt/β-catenin pathway by IPA
Symbol Gene name log2 Fold Change Location Type(s)
ACVR1C activin A receptor, type IC −3.029 Plasma Membrane kinase
GNAQ guanine nucleotide binding protein (G protein), q polypeptide −2.877 Plasma Membrane enzyme
SOX13 SRY (sex determining region Y)-box 13 −2.877 Nucleus transcription regulator
WIF1 WNT inhibitory factor 1 −2.877 Extracellular Space other
CDH2 cadherin 2, type 1, N-cadherin (neuronal) −2.708 Plasma Membrane other
PPP2R2A protein phosphatase 2, regulatory subunit B, alpha −2.708 Cytoplasm phosphatase
TGFB3 transforming growth factor, beta 3 −2.708 Extracellular Space growth factor
PPP2R1B protein phosphatase 2, regulatory subunit A, beta −2.614 Plasma Membrane phosphatase
CSNK1G3 casein kinase 1, gamma 3 −2.515 Cytoplasm kinase
WNT11 wingless-type MMTV integration site family, member 11 −2.515 Extracellular Space other
MARK2 MAP/microtubule affinity-regulating kinase 2 −2.292 Cytoplasm kinase
WNT7A wingless-type MMTV integration site family, member 7A −2.292 Extracellular Space cytokine
TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box) −2.167 Nucleus transcription regulator
GJA1 gap junction protein, alpha 1, 43 kDa −2.029 Plasma Membrane transporter
PPP2R2B protein phosphatase 2, regulatory subunit B, beta −2.029 Cytoplasm phosphatase
PPP2R5A protein phosphatase 2, regulatory subunit B’, alpha −2.029 Cytoplasm phosphatase
SFRP2 secreted frizzled-related protein 2 −2.029 Plasma Membrane transmembrane receptor
SOX7 SRY (sex determining region Y)-box 7 −2.029 Nucleus transcription regulator
SOX14 SRY (sex determining region Y)-box 14 −2.029 Nucleus transcription regulator
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) −2.029 Nucleus transcription regulator
TLE3 transducin-like enhancer of split 3 −2.029 Nucleus other
WNT7B wingless-type MMTV integration site family, member 7B −2.029 Extracellular Space other
WNT8B wingless-type MMTV integration site family, member 8B −2.029 Extracellular Space other
Guo et al. Cell & Bioscience  (2015) 5:24 Page 14 of 17tissue from three Apc+/+ littermates using a DNeasy Kit
(Qiagen, Valencia, CA, USA). Prior to fragmentation by
Covaris (Covaris, Inc., Woburn, MA, USA), the quality
of the extracted genomic DNA was confirmed by agar-
ose gel electrophoresis and OD ratio. After fragmenta-
tion, the genomic DNA was further assessed for size
distribution using an Agilent Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA, USA). The fragmented
genomic DNA concentrations were measured with a
Nanodrop spectrophotometer.
MeDIP-seq
MeDIP was performed using a MagMedIP kit (Diage-
node, Denville, NJ, USA) as previously described [63].
Briefly, immunoprecipitations were performed using a
monoclonal antibody against 5-methylcytidine (Diage-
node, Denville, NJ, USA) to separate the methylated
DNA fragments from the unmethylated fragments. The
captured DNA was used to create the Illumina libraries
using NEBNext reagents (catalog# E6040; New England
Biolabs, Ipswich, MA, USA). After the quality of the li-
braries was evaluated, the samples were sequenced usingan Illumina HiSeq 2000 machine. The results were ana-
lyzed for data quality and exon coverage using the plat-
form provided by DNAnexus (DNAnexus, Inc.,
Mountain View, CA, USA). Subsequently, the samples
were subjected to Illumina next-generation sequencing
(Otogenetics Corporation, Norcross, GA, USA). After
downloading the BAM files for analysis, MeDIP align-
ments were compared with control samples using Cuff-
diff 2.0.2 as previously described [64, 63]. To judge the
quantitative enrichment in MeDIP samples versus con-
trol samples in Cuffdiff, the overlapping regions of se-
quence alignment common to the MeDIP and control
samples were used. Significant peaks at a 5 % false dis-
covery rate (FDR) with a minimum of a 4-fold difference
in R (Cummerbund package) were selected. The peaks
were matched with adjacent annotated genes using
ChIPpeakAnno as previously described [65].
Ingenuity Pathway Analysis (IPA)
To investigate the significance of the altered methylation
observed by MeDIP-seq, we analyzed genes that exhib-
ited greater than a 2-fold change (log2) in methylation
Fig. 5 Predicted interactions between molecules with altered methylation that mapped to the EMT and Wnt/β-catenin pathways. IPA predicted
direct interaction of the genes with altered methylation patterns in the EMT and Wnt/β-catenin pathways based on the publication database.
Red, increased methylation; green, decreased methylation
Guo et al. Cell & Bioscience  (2015) 5:24 Page 15 of 17(Apcmin/+ polyps vs. control) using IPA (IPA 4.0, Ingenu-
ity Systems, www.ingenuity.com). IPA utilized gene sym-
bols that were identified as neighboring enriched
methylation peaks by ChIPpeakAnno for all of the ana-
lyses. IPA mapped the input genes to its knowledge bases
and identified the most relevant biological functions, net-
works, and canonical pathways related to the altered
methylation profiles in the Apc mutant polyps.
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